prikaz prve stranice dokumenta Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma
  Download
PDF 7.45 MB
Scientific paper - Original scientific paper
Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma
Biomedicines, 10 (2021), 1; 89. https://doi.org/10.3390/biomedicines10010089
Kralj, Tamara; Kokot, Antonio; Zlatar, Mirna; Masnec, Sanja; Kasnik Kovac, Katarina; Milković Periša, Marija; Batelja Vuletić, Lovorka; Giljanović, Ana; Štrbe, Sanja; Sikirić, Sunčana; Balog, Slaven; Sontacchi, Bojan; Sontacchi, Dijana; Buljan, Matko; Lovrić, Eva; Boban Blagaić, Alenka; Škrtić, Anita; Seiwerth, Sven; Sikirić, Predrag More authors...

Citations: ,
Scopus (20)

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Kralj, T., Kokot, A., Zlatar, M., Masnec, S., Kasnik Kovac, K., Milković Periša, M. ... Sikirić, P. (2021). Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma. Biomedicines, 10. (1). doi: 10.3390/biomedicines10010089

Kralj, Tamara, et al. "Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma." Biomedicines, vol. 10, no. 1, 2021. https://doi.org/10.3390/biomedicines10010089

Kralj, Tamara, Antonio Kokot, Mirna Zlatar, Sanja Masnec, Katarina Kasnik Kovac, Marija Milković Periša, Lovorka Batelja Vuletić, et al. "Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma." Biomedicines 10, no. 1 (2021). https://doi.org/10.3390/biomedicines10010089

Kralj, T., et al. (2021) 'Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma', Biomedicines, 10(1). doi: 10.3390/biomedicines10010089

Kralj T, Kokot A, Zlatar M, Masnec S, Kasnik Kovac K, Milković Periša M, and sur.. Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma. Biomedicines [Internet]. 2021 December 31 [cited 2025 April 02];10(1). doi: 10.3390/biomedicines10010089

T. Kralj, et al., "Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma", Biomedicines, vol. 10, no. 1, December 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:200123. [Accessed: 02 April 2025]

Metadata
Title (english)Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma
AuthorTamara Kralj
AuthorAntonio Kokot
AuthorMirna Zlatar
AuthorSanja Masnec
AuthorKatarina Kasnik Kovac
AuthorMarija Milković Periša
AuthorLovorka Batelja Vuletić
AuthorAna Giljanović
AuthorSanja Štrbe
MBZ: 319335
AuthorSunčana Sikirić
AuthorSlaven Balog
AuthorBojan Sontacchi
AuthorDijana Sontacchi
AuthorMatko Buljan
AuthorEva Lovrić
AuthorAlenka Boban Blagaić
AuthorAnita Škrtić
AuthorSven Seiwerth
AuthorPredrag Sikirić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pharmacology)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pathology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Pharmacology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Abstract (english)
Cauterization of three episcleral veins (open-angle glaucoma model) induces venous congestion and increases intraocular pressure in rats. If not upgraded, one episcleral vein is regularly unable to acquire and take over the whole function, and glaucoma-like features persist. Recently, the rapid upgrading of the collateral pathways by a stable gastric pentadecapeptide BPC 157 has cured many severe syndromes induced by permanent occlusion of major vessels, veins and/or arteries, peripherally and... More centrally. In a six-week study, medication was given prophylactically (immediately before glaucoma surgery, i.e., three episcleral veins cauterization) or as curative treatment (starting at 24 h after glaucoma surgery). The daily regimen of BPC 157 (0.4 µg/eye, 0.4 ng/eye; 10 µg/kg, 10 ng/kg) was administered locally as drops in each eye, intraperitoneally (last application at 24 h before sacrifice) or per-orally in drinking water (0.16 µg/mL, 0.16 ng/mL, 12 mL/rat until the sacrifice, first application being intragastric). Consequently, all BPC 157 regimens immediately normalized intraocular pressure. BPC 157-treated rats exhibited normal pupil diameter, microscopically well-preserved ganglion cells and optic nerve presentation, normal fundus presentation, normal retinal and choroidal blood vessel presentation and normal optic nerve presentation. As leading symptoms, increased intraocular pressure and mydriasis, as well as degeneration of retinal ganglion cells, optic nerve head excavation and reduction in optic nerve thickness, generalized severe irregularity of retinal vessels, faint presentation of choroidal vessels and severe optic nerve disc atrophy were all counteracted. In conclusion, we claim that the reversal of the episcleral veins cauterization glaucoma appeared as a consequence of the BPC 157 therapy of the vessel occlusion-induced perilous syndrome. Less
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBiomedicines
Numberingvol. 10, no. 1, 89
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines10010089
URN:NBNurn:nbn:hr:105:200123
Publication2021-12-31
Document URLhttps://www.mdpi.com/2227-9059/10/1/89
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-07-01 06:54:30
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.